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Introduction {#sec1}
============

Long non-coding RNAs (lncRNAs) have emerged as important regulators of heart development and disease ([@bib38], [@bib59]). Several lncRNAs such as *Braveheart* ([@bib25]), *Fendrr* ([@bib13]), *Upperhand* ([@bib4]), and *Carmen* ([@bib52]) are differentially activated at the fetal and adult stages of cardiac development. Although the precise roles of these lncRNAs still remain poorly understood, recent evidence suggests that lncRNAs not only control mRNA expression during the critical transition stages from fetal to adult heart but also function with mRNA stability, decay, and as regulatory sponges ([@bib68]). Not entirely unexpected, in the fetal heart, lncRNAs associate more with genes implicated in processes that involve development and programming, whereas in the adult heart lncRNAs associate more with genes involved in disease. For example, in the adult heart the expression of lncRNAs *Chast* ([@bib66]), *Chaer* ([@bib69]), and *Wisper* ([@bib44]) are linked with cardiac hypertrophy and fibrosis. The sarcomeric myosin heavy chain (MHC) isogenes, originally designated α and β (recently renamed *Myh6* and *Myh7*) are predominantly expressed in the heart ([@bib37], [@bib36]). During fetal life *Myh7* is principally expressed, whereas *Myh6* and *Myh7* are simultaneously expressed shortly after birth, with *Myh6* dominantly expressed in adulthood ([@bib9], [@bib30], [@bib31]). During myocardial hypertrophy *Myh7* is selectively expressed under hemodynamic and pressure overload ([@bib20], [@bib29], [@bib32]).

Previously known as antisense *β-MHC* ([@bib15]), *Myosin heavy-chain-associated RNA transcript* (*Myheart*, *or Mhrt*) is a myocardium-specific lncRNA regulated by antisense transcription of a specific intergenic promoter that originates from the antisense strand of *Myh7* that serves as a switch for *Myh6/7* gene expression ([@bib16]). Recent studies have shown that *Mhrt* expression is cardioprotective and behaves as a decoy lncRNA involved in a negative feedback circuit with chromatin remodeling. Interestingly, cardiac hypertrophy induced by pressure overload in a mouse model progressively reduced *Mhrt* expression. Experiments have shown that restoring *Mhrt* to prestress levels can attenuate cardiac damage and rescue the heart from pathological hypertrophy ([@bib16]). It is hypothesized that under cardiac stress *Mhrt* restores the *Myh6/7* gene shift by virtue of its interaction with the remodeling enzyme, Brg1, an ATP-dependent DNA helicase and a subunit of a much larger SWI/SNF complex. We have recently shown that *pri-miR-208b*, an lncRNA that originates from *Myh7*, regulates gene expression during cardiac hypertrophy ([@bib39]). Upon transverse aortic constriction (TAC) in a mouse model of pathological hypertrophy, the left ventricular tissue shows elevated expression of *pri-miR-208b* that interacts with a Polycomb-group protein, Ezh2, and is part of a Hdac complex that regulates the *Myh6/7* gene shift ([@bib39]). The precise mechanisms regulating sex-based expression of lncRNAs such as *pri-miR-208b* and *Mhrt* remain poorly characterized.

Gender disparity in cardiovascular health and disease is well documented with females generally regarded less vulnerable to pathological cardiac remodeling ([@bib35]). Pathogenic processes such as cardiomyocyte apoptosis and necrosis characteristic of hypertrophy occur predominantly in males ([@bib14]). Pathological cardiac hypertrophy is characterized by reactivation of fetal gene programming that involves activation of fetal genes and the suppression of genes expressed in adults ([@bib12]). This pattern of expression is common to both sexes, whereas molecular remodeling induced by pressure overload hypertrophy occurs predominantly in males ([@bib70], [@bib74]). Sex differences in the heart are largely determined by steroid hormones; however, several histone modifiers and methyl-binding proteins as well as promoter DNA methylation are closely linked to sex-based gene expression during development and in adult heart ([@bib26], [@bib55]). The role of lncRNAs in regulating sex-based gene expression by methylation in the heart remain poorly characterized. Because lncRNAs can interact with epigenetic modifiers, our aim was to determine the mechanism of lncRNA methylation in regulating sex-based gene expression in the heart.

MeCP2 is a reader of DNA methylation, a component of a co-repressor complex ([@bib18]) and recently shown to regulate gene expression in chronic heart failure ([@bib41]). In addition to its high affinity for methylated cytosine sites on DNA, MeCP2 is recognized for its ability to bind RNA and regulate alternative splicing events by interacting with YB-1 ([@bib72], [@bib33], [@bib21]). Although MeCP2 was initially characterized as a reader with high affinity for methylated cytosine in DNA ([@bib6]), more recent studies have shown that MeCP2 can interact with other RNAs ([@bib40], [@bib23], [@bib24]). For example, MeCP2 has been shown to interact with mRNAs ([@bib33]); non-coding RNAs (ncRNAs) such as *let-7i*, *miR-375,* and *miR-126* ([@bib24]); as well as *Rncr3* and *Malat1* ([@bib40]). Although these studies suggest that MeCP2 interacts with RNA to suppress gene expression, the mechanism mediated by lncRNA in the myocardium remains poorly understood.

One mechanism recently identified in the epigenetic control of lncRNAs is the deposition of 5-methylcytosine (5mC) ([@bib62], [@bib3]). This epigenetic determinant occurs on coding RNA and ncRNA, and several lncRNAs such as *Xist*, *Hotair,* and *Malat1* contain 5mC sites and have been shown to regulate ncRNA function ([@bib3], [@bib2]). The purpose of this study was to explore the sex-based differences in lncRNA expression in the heart. Recent studies have shown that RNA-dependent MeCP2 binding on genes is independent of DNA methylation ([@bib23]). Therefore, we hypothesized that sex-based interaction of MeCP2 at the pri-miR-208b promoter is associated with *Mhrt* lncRNA methylation. Close examination of DNA methylation at the *pri-miR-208b* promoter using bisulfite sequencing identified nine sites of cytosine methylation at the CpG island (CGI). We observed no difference in DNA methylation between the sexes but show dramatic changes in the binding of the methylation reader, MeCP2, on the *pri-miR-208b* promoter using chromatin immunoprecipitation (ChIP). We identified that sex-specific expression of *pri-miR-208b* in the female heart is independent of DNA methylation. We provide proof of concept that MeCP2 affinity to chromatin is subject to RNA-methylation-dependent regulation. Sex-specific methylation of *Mhrt* distinguishes MeCP2 chromatinization of the *pri-miR-208b* promoter and gene regulation in the female heart.

Results {#sec2}
=======

Sex Differences in *Primary miR-208b* Expression in the Heart {#sec2.1}
-------------------------------------------------------------

In the heart, cardiac myosin heavy chain (*Myh*) genes are transcriptionally regulated by distinct promoters that give rise to protein-coding genes and ncRNA production ([Figure 1](#fig1){ref-type="fig"}A). Located between *Myh6* and *Myh7* genes ([@bib16], [@bib39]) the promoter serves to regulate the transcription of the antisense lncRNA, *Mhrt*. To investigate gender differences in ncRNA expression we used qRT-PCR. *Myh*-encoded RNAs show sex-based differences in the expression of *pri-miR-208b* and *Myh6* in female left ventricles when compared with males ([Figures 1](#fig1){ref-type="fig"}B and 1C). In contrast, we observe no significant differences in the expression of *Myh7*, *Mhrt,* and mature *miR-208b* transcripts ([Figures 1](#fig1){ref-type="fig"}D--1F).Figure 1Elevated *Primary miR-208b* (*pri-miR-208b*) Transcript in Female Left Ventricle(A) Genomic organization of myosin heavy chain coding and non-coding genes on chromosome 14 of mouse. qRT-PCR quantification of (B) *pri-miR-208b*; (C) *Myh6*; (D) *Myh7*, p = 0.065; (E) *Mhrt* (also known as antisense *β-MHC*); and (F) *miR-208b*. Normalized to *Gapdh*. CGI, CpG island; TSS, transcription start site; ns, not significant. \*p \< 0.05, \*\*p \< 0.01. n = 5 mice per group. Data are represented as mean ± SEM.

To understand the regulation of *pri-miR-208b* transcript, we examined its promoter located within exon 28 of mouse *Myh7* gene ([Figure 2](#fig2){ref-type="fig"}A) ([@bib45], [@bib65]). The majority of RNA Pol II promoters are marked by CGI ([@bib34], [@bib7], [@bib53]) and served by specific bidirectional promoters (bdPs) ([@bib63]). The promoter initiating *pri-miR-208b* transcription has a CGI that is conserved between mouse and human *Myh* orthologs ([Figure 2](#fig2){ref-type="fig"}A, CGI shown in green). Bisulfite sequencing identified nine CG sites (located at positions 14, 19, 20, 22, 23, 24, 25, 27, and 28) that are methylated in the promoter but were indistinguishable between male and female heart tissues ([Figure 2](#fig2){ref-type="fig"}B). Although these results suggest that *pri-miR-208b* promoter is methylated at specific CG dinucleotides, DNA methylation alone does not explain sex-based differences in *pri-miR-208b* expression.Figure 2Interaction of the MeCP2 Reader on the *pri-miR-208b* Promoter in Female Left Ventricle Is Independent of DNA Methylation and Involves RNA Interactions(A) Exon 28 of *Myh7* gene showing *pri-miR-208b* promoter with CpG Island (CGI). CGI sequence within *pri-miR-208b* promoter is conserved between mice and humans.(B) Bisulfite conversion and DNA methylation show site-specific CG methylation in male and female left ventricle (LV).(C) Procedure of ChIP coupled with ribonuclease degradation (+RNase A) to assess cardiac RNA-dependent interactions.(D and E) (D) Specific binding of MeCP2 at *pri-miR-208b* promoter in male and female LV in the presence (+) or absence (−) of RNase A. (E) Intergenic promoter is shown as a control for methyl CpG-binding proteins.(F) Representative immunoblots of MeCP2 protein expression in male and female LV. Bar graph represents mean values of LI-COR Odyssey quantification of protein blots normalized to histone H3.\*\*p \< 0.01. n ≥ 4 mice per group. Data are represented as mean ± SEM. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Sex-Specific Affinity for MeCP2 with *Pri-miR-208b* Chromatin Is RNA Dependent {#sec2.2}
------------------------------------------------------------------------------

Methyl-CpG-binding protein-mediated gene suppression involves the recognition of DNA methylation at CG dinucleotides at gene promoters, and recent experimental evidence implicates a regulatory role for MeCP2 in the mouse heart ([@bib41]). As *pri-miR-208b* promoter is methylated we assessed expression and chromatin interaction of methyl CpG-binding proteins in male and female hearts. qRT-PCR analysis shows no significant differences in the expression of *Mecp2*, *Mbd1*, *Mbd2,* and *Mbd3* transcripts between the sexes ([Figure S1](#mmc1){ref-type="supplementary-material"}). As the *pri-miR-208b* promoter is methylated albeit indistinguishably between sexes, we examined the binding specificities of protein readers of DNA methylation, members of the methyl-CpG-binding domain assessed by ChIP assays. Antibodies that specifically recognize MeCP2, MBD1, MBD2, and MBD3 were used to immunopurify soluble chromatin, followed by nucleic acid purification and quantification by qPCR. This technique specifically detects chromatin-bound MeCP2 fractions, whereas the protocol does not distinguish RNA-dependent interactions ([Figure 2](#fig2){ref-type="fig"}C, --RNase A). The specificity of antibody enrichment for *pri-miR-208b* chromatin was also assessed using IgG antibody controls (data not shown). As shown in [Figure 2](#fig2){ref-type="fig"}D, soluble chromatin was significantly enriched for MeCP2 on the *pri-miR-208b* promoter when compared with antibodies that recognize the other methyl-CpG-binding proteins. We also observed sex-based differences in chromatinized MeCP2 on the *pri-miR-208b* promoter ([Figure 2](#fig2){ref-type="fig"}D, --RNase A). We confirm that the affinity for MeCP2 was specific for the *pri-miR-208b* promoter when compared with the intergenic region ([Figure 2](#fig2){ref-type="fig"}E). Because these results were inconsistent with DNA methylation observed at the *pri-miR-208b* promoter ([Figure 2](#fig2){ref-type="fig"}B) we proposed that sex-based differences in MeCP2 affinity on soluble chromatin could be RNA dependent.

To test this hypothesis further, we devised a ChIP protocol that involves ribonuclease degradation ([Figure 2](#fig2){ref-type="fig"}C, +RNase A) to assess cardiac RNA-dependent MeCP2 affinity with the *pri-miR-208b* promoter ([@bib23], [@bib24], [@bib40], [@bib39]). To test the feasibility of this approach, soluble MeCP2-associated chromatin fractions were subject to endoribonuclease A (+RNase A) to catalyze the cleavage of chromatin-associated RNA molecules. We observed significant reduction of MeCP2 affinity on the *pri-miR-208b* promoter in RNase-treated cardiac chromatin ([Figure 2](#fig2){ref-type="fig"}D, +RNase A). Furthermore, the qPCR signal for MeCP2 by ChIP was reduced for the *pri-miR-208b* promoter in the female heart. To confirm that the loss of MeCP2 binding following RNase exposure was specific for the *pri-miR-208b* promoter, we also assessed the intergenic region that is known to give rise to *Myh6/Myh7* transcript diversity. Irrespective of sex we recovered the intergenic region equally well from chromatin isolates using MeCP2 antibody ([Figure 2](#fig2){ref-type="fig"}E). Furthermore, we assessed fractionated MeCP2 protein levels in the heart. Quantitative analysis of MeCP2 using LI-COR Odyssey imaging system show comparable protein expression from male and female heart tissue ([Figure 2](#fig2){ref-type="fig"}F), which is consistent with comparable mRNA expression ([Figure S1](#mmc1){ref-type="supplementary-material"}). Taken together, these experimental results derived from soluble chromatin fractions using specific endoribonuclease assays further reinforce the view that *pri-miR-208b* promoter is subject to RNA-dependent MeCP2 binding.

Affinity of Rest and Hdac2 on *Pri-miR-208b* Chromatin Is RNA Dependent {#sec2.3}
-----------------------------------------------------------------------

MeCP2 binds methylated DNA on assembled chromatin to recruit the RE1-silencing transcription factor (Rest) and histone deacetylase 2 (Hdac2) to repress gene transcription ([@bib50], [@bib51]). *In silico* analysis of *pri-miR-208b* promoter shows transcription factor-binding sites for Rest co-repressor protein ([Figure S2](#mmc1){ref-type="supplementary-material"}). We assessed whether Rest and Hdac2 affinities for the *pri-miR-208b* promoter are subject to RNA-mediated interactions using specific ChIP assays. Consistent with previous results in the female heart, we observe reduced binding of Rest on the *pri-miR-208b* promoter by ChIP (--RNase A) and confirm that RNA is a substrate for binding (+RNase A), as shown in [Figure 3](#fig3){ref-type="fig"}A. Specificity for the *pri-miR-208b* promoter was shown by near-comparable Rest binding with the intergenic promoter in both sexes. Apart from the requirement for RNA to bind Rest to the *pri-miR-208b* promoter we observe no distinguishable difference at the intergenic promoter ([Figure 3](#fig3){ref-type="fig"}A). We also assessed Hdac2-associated chromatin fragments and confirm that affinity for the *pri-miR-208b* promoter is sensitive to nuclease degradation and in part mediated by RNA ([Figure 3](#fig3){ref-type="fig"}B, +RNase A). Taken together, these observations strengthen the view that sex-based affinity of the co-repressor complex at *pri-miR-208b* promoter is sensitive to endoribonuclease digestion and thus places specific emphasis on RNA-dependent interactions.Figure 3MeCP2 Forms an RNA/dsDNA Hybrid with *Mhrt* and *pri-miR-208b*(A and B) Chromatin immunoprecipitation of (A) Rest and (B) Hdac2 binding at *pri-miR-208b* promoter in male and female LV in the presence (+) or absence (−) of RNase A.(C) Enlarged view of the RNA/DNA hybrid region in predicted secondary structure of full-length *Mhrt* (also shown in [Figure S3](#mmc1){ref-type="supplementary-material"}). The predicted *Mhrt* lncRNA (shown in orange)/DNA hybrid sequence at the *pri-miR-208b* promoter (shown in black). Twenty-five CG dinucleotides of *Mhrt* lncRNA are shown in red.(D) *In vitro* reconstitution assay showing qPCR amplification of *pri-miR-208b* promoter after hybridization with *Mhrt* oligomer in the presence of RNase H or RNase V1.(E) Amplification of *pri-miR-208b* promoter by qPCR after MeCP2 immunopurification from the *Mhrt* RNA-dsDNA hybrid.\*p \< 0.05. \*\*\*\*p \< 0.0001. Data are represented as mean ± SEM. See also [Figures S2--S4](#mmc1){ref-type="supplementary-material"}.

*Mhrt* Forms Stable RNA:dsDNA Hybrid with *Pri-miR-208b* Promoter {#sec2.4}
-----------------------------------------------------------------

lncRNAs have emerged as a class of gene regulators that serve to alter chromatin structure and gene function ([@bib43], [@bib38]). lncRNAs can form stable RNA-DNA hybrids and act as docking sites for transcription factors ([@bib58], [@bib13], [@bib39], [@bib54]). A recent study has shown that stress-induced interaction of *Mhrt* with the Brg1 complex regulates the *Myh6/7* gene shift in the heart ([@bib16]). Therefore, we assessed whether *Mhrt* could bind the *pri-miR-208b* chromatin. *In silico* analysis identified a 37-nucleotide (nt) binding site for *Mhrt* RNA (CG8-9 correspond to positions 141--178: [Figure S3](#mmc1){ref-type="supplementary-material"}) downstream of the *pri-miR-208b* transcription start site ([Figure 3](#fig3){ref-type="fig"}C). To assess whether *Mhrt* could form stable hybrid (RNA:dsDNA \[double-stranded DNA\]) with *pri-miR-208b* promoter, we performed binding assays using *Mhrt* RNA oligomer corresponding to the 37-nt sequence and dsDNA matching the *pri-miR-208b* promoter sequence ([@bib13], [@bib39]). Because the RNA oligomer (RNAmer) was constructed with biotin label at the 3′ end of *Mhrt* this allowed for immunopurification using streptavidin beads. Incubation of RNA and dsDNA followed by streptavidin capture and qPCR amplification of *pri-miR-208b* promoter shows high affinity for the *Mhrt* oligomer ([Figure 3](#fig3){ref-type="fig"}D, --RNase). However, in the presence of RNase H, which specifically cleaves RNA in an RNA:dsDNA hybrid ([@bib13], [@bib39]), the qPCR signal for *pri-miR-208b* was significantly reduced ([Figure 3](#fig3){ref-type="fig"}D, +RNase H). To further illustrate the specificity of RNA binding we used RNase V1, which cleaves base-paired RNA nucleotides ([@bib13], [@bib27]), to confirm that *Mhrt* interacts directly with *pri-miR-208b* promoter ([Figure 3](#fig3){ref-type="fig"}D, +RNase V1).

Because MeCP2 binding is sensitive to RNA nuclease degradation we assessed binding to RNA:dsDNA hybrids. To do this, binding assays were performed using recombinant MeCP2 in the presence or absence of RNA (full-length *Mhrt*):dsDNA (*Pri-miR-208b*) hybrids. We made use of selective mixtures of RNA:dsDNA hybrids to test the sensitivity to RNase H nuclease digestion following immunopurification using an antibody that specifically recognizes MeCP2. Isolated DNA was assayed by qPCR detection of the *pri-miR-208b* promoter ([Figure S4](#mmc1){ref-type="supplementary-material"}). Under optimal binding conditions, we observe no qPCR signal for the *pri-miR-208b* promoter using the MeCP2 antibody. Under identical reaction conditions, we found that MeCP2 was significantly enriched on the *pri-miR-208b* promoter in the presence of full-length *Mhrt* RNA ([Figure 3](#fig3){ref-type="fig"}E). RNA transcripts fold into secondary structures critical to form RNA-DNA interactions as predicted by the minimal free energy of *Mhrt* transcript ([Figure S3](#mmc1){ref-type="supplementary-material"}). Interestingly, CG18 is the nearest dinucleotide site in the hybrid region ([Figure 3](#fig3){ref-type="fig"}C). To assess the hybrid region of *Mhrt* transcript, we performed MeCP2 binding assays using CG8-9 and CG17-19 *Mhrt* RNAmers as well as the full-length *Mhrt* transcript ([Figure 3](#fig3){ref-type="fig"}E). CG8-9 and CG17-19 displayed strong affinity for recombinant MeCP2 protein. To test the binding specificity under identical reaction conditions we also assessed the interaction of recombinant Set7 methyltransferase, which does not recognize methylated DNA. We confirm that Set7 does not interact with the RNA:dsDNA hybrid (personal observations). The interaction of MeCP2 with *Mhrt* and *pri-miR-208b* duplex led us to examine whether this affinity was sensitive to RNase H nuclease digestion. Following MeCP2 immunoprecipitation capture the signal for *pri-miR-208b* promoter was barely detectable. These results support the view that MeCP2 affinity for the *pri-miR-208b* promoter is mediated by CG8-9 and CG17-19 interaction for *Mhrt* lncRNA.

*Mhrt* Methylation Distinguishes Sex-Based Differences in MeCP2 Binding {#sec2.5}
-----------------------------------------------------------------------

Because *Mhrt* has been shown to function as decoy lncRNA by interacting with Brg1 in cardiac hypertrophy ([@bib16]), we hypothesized that *Mhrt* could interact with MeCP2. To do this, we isolated RNA from soluble chromatin fractions immunopurified using anti-MeCP2 antibody, and tested binding affinities for *Mhrt* using qPCR detection. We observe sex-based differences for MeCP2 affinity on *Mhrt* using a specific RNA-ChIP procedure ([Figures 4](#fig4){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}). The affinity of MeCP2 for *Mhrt* was significantly reduced in +RNase A-treated chromatin when compared with IgG antibody controls ([Figure S5](#mmc1){ref-type="supplementary-material"}). Although these results imply MeCP2 interacts with *Mhrt,* the affinity for the lncRNA remains poorly characterized.Figure 4*Mhrt* Is Methylated and Binds to MeCP2 in Female Left Ventricle(A) RNA-ChIP using anti-MeCP2 antibody showing *Mhrt* interaction with MeCP2-bound chromatin in male and female left ventricle (LV). n = 6 mice per group.(B) Illustration of 0.828 kb of *Mhrt* lncRNA with 25 CG dinucleotides and regions A-E targeted by bisulfite primers.(C) Bisulfite-converted *Mhrt* clones showing methylation at CG18 of *Mhrt* lncRNA in female LV. n = 5 mice per group.(D) Synthetic 45-nt-long *Mhrt* oligomer highlighting CG17-19 and variants with replaced cytosine to adenosine residues.(E) Quantification of *Mhrt*-MeCP2 binding assay showing enhanced MeCP2 binding after methylation of synthetic *Mhrt* oligomer.(F) RNA-dsDNA hybrid binding assay showing methylation-dependent affinity of MeCP2 for CG17-19 *Mhrt* RNAmer.\*p \< 0.05, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001. Data are represented as mean ± SEM. See also [Figures S5--S8](#mmc1){ref-type="supplementary-material"}.

Recent studies show that post-transcriptional RNA modifications are implicated in transcriptional control ([@bib3], [@bib62]). We hypothesized that the affinity of the methylation reader MeCP2 is dependent on 5mC deposition on *Mhrt* lncRNA. To do this we examined the possible methylation sites at 25 CG dinucleotides ([Figure S6](#mmc1){ref-type="supplementary-material"}) using bisulfite sequencing of five distinct regions labeled A-E that cover the *Mhrt* lncRNA ([Figure 4](#fig4){ref-type="fig"}B). RNA methylation analysis showed sex specific methylation at CG18 position detectable in 25% of total clones tested for this site in female heart tissues ([Figure 4](#fig4){ref-type="fig"}C). We observed no RNA methylation for other CG sites of the *Mhrt* transcript in male and female hearts. These results suggest that specific cytosine methylation at position CG18 of *Mhrt* could distinguish sex-specific affinity for MeCP2.

MeCP2 Binds Methylated *Mhrt* lncRNA {#sec2.6}
------------------------------------

To investigate site-specific *Mhrt* methylation and MeCP2 interaction, we designed biotin-tagged synthetic RNAmers that include CG17, CG18, and CG19 sites of the *Mhrt* transcript ([Figure 4](#fig4){ref-type="fig"}D). The CG18 site of the *Mhrt* transcript is conserved in humans and mice, suggesting that it could be important for MeCP2 affinity ([Figure S6](#mmc1){ref-type="supplementary-material"}). To specifically examine methylation at CG18 we designed RNAmers that replaced cytosine residues with adenosine ([Figure 4](#fig4){ref-type="fig"}D). *Mhrt* oligomer-1 contained three CGs intact (CG17-19), oligomer-2 contained "C" replaced with "A" at all three sites, and oligomer-3 contained "C" replaced with "A" only at CG17 and CG19, thus leaving CG18 intact. To assess the affinity for methylated CG18, RNAmers were reconstituted with recombinant MeCP2 followed by immunopurification using streptavidin beads. Quantitative protein blotting using LI-COR Odyssey was performed using an antibody that specifically recognizes MeCP2 ([Figure S7](#mmc1){ref-type="supplementary-material"}). To assess MeCP2 affinity for the methylated and unmethylated RNAmers *M*.*Sss1* methyltransferase ([@bib11]) was used to specifically methylate CG17-19 sites. We observed binding of recombinant MeCP2 when incubated with unmethylated CG17-19 *Mhrt* RNAmer ([Figure 4](#fig4){ref-type="fig"}E, panel A); however, the affinity for MeCP2 was significantly enriched in the presence of methylated CG17-19 *Mhrt* RNAmer ([Figure 4](#fig4){ref-type="fig"}E, panel B). Binding for MeCP2 was competed when incubated with oligomer-2, suggesting that the CG18 site is an important substrate for binding ([Figure 4](#fig4){ref-type="fig"}E, panel C). In support of this viewpoint, the affinity of MeCP2 was restored when site position CG18 was methylated using oligomer-3 ([Figure 4](#fig4){ref-type="fig"}E, panel E) when compared with the unmethylated version ([Figure 4](#fig4){ref-type="fig"}E, panel D). Furthermore, we confirm that MeCP2 affinity was RNA dependent using ribonuclease A ([Figure 4](#fig4){ref-type="fig"}E, MeCP2+RNase A). To illustrate the specificity of MeCP2 affinity for *Mhrt* we assessed binding of the lysine methyltransferase writer Set7, which neither distinguishes methylated DNA nor binds RNA. We confirm that Set7 does not interact with methylated RNAmers, confirming the affinity of MeCP2 for methylated *Mhrt* at CG18 site ([Figure 4](#fig4){ref-type="fig"}E). These results support the view that CG18 methylation could account for MeCP2 affinity to *Mhrt* lncRNA. Based on these results we examined the expression of known RNA methyltransferase transcripts (*Nsun2*, *Nsun4*, *Nsun5*, *Rnmt1*, *Nop2*, *Trdmt1*, *Mrm1*, *Trmt1*) in male and female tissues. There was no significant difference in the expression of RNA methyltransferases ([Figure S8](#mmc1){ref-type="supplementary-material"}).

To assess whether *Mhrt* methylation influences the affinity of MeCP2-dependent formation with *pri-miR-208b* promoter, we performed RNA:dsDNA hybrid assays using methylated/unmethylated CG17-19 *Mhrt* RNAmers (oligomer-1 in [Figure 4](#fig4){ref-type="fig"}D). We made use of selective mixtures of RNA:dsDNA hybrids to test the sensitivity to RNase H digestion following immunopurification using an antibody that specifically recognizes MeCP2. Isolated DNA was assayed by qPCR detection of the *pri-miR-208b* promoter ([Figure S4](#mmc1){ref-type="supplementary-material"}). Consistent with the binding affinity of MeCP2 with *Mhrt* in the female heart, MeCP2 was significantly enriched on the *pri-miR-208b* promoter when *Mhrt* is specifically methylated at CG17-19 following capture by RNA immunoprecipitation ([Figure 4](#fig4){ref-type="fig"}F --RNase H). The qPCR signal for the *pri-miR-208b* promoter was almost abolished using identical binding conditions and ribonuclease endonuclease H enzyme that catalyzes the cleavage of RNA in an RNA/DNA hybrid ([Figure 4](#fig4){ref-type="fig"}F + RNase H). Taken together, these results suggest that the affinity of MeCP2 for the RNA:dsDNA hybrid is likely to depend on *Mhrt* methylation to chromatinize the *pri-miR-208b* promoter to regulate gene transcription.

Discussion {#sec3}
==========

Although sex-based differences in the incidence, prevalence, and severity of cardiovascular disease are well documented the functional mechanisms underlying sex-specific gene expression remains poorly understood. Whether sexual dimorphism is functionally regulated by methylation of DNA and RNA nucleobases remains uncharted in the heart.

It is probable that methylation of *Mhrt* that we describe is responsible for sex-based differences in *pri-miR-208b* expression. The proposed model is mediated by DNA methylation, which we speculate is functioning in a context-dependent manner on the *pri-miR-208b* promoter and distinct from the exclusive RNA methylation observed in *Mhrt* in females. This is because, irrespective of sex, the *pri-miR-208b* promoter is characterized by CGI methylation at nine identical sites. Close inspection of *Mhrt* and *pri-miR-208b* lncRNAs shows several interesting features. First, *Mhrt* is methylated in female heart tissue and the presence of RNA methylation at the CG18 site may indicate regulatory function that is associated with MeCP2 affinity. Second, irrespective of sex the *pri-miR-208b* promoter is methylated at nine identical CG sites and represents default repression. We believe that interactions mediated by DNA and RNA methylation are context specific, meaning MeCP2 assembles on methyl-CG sites and cooperatively serves to suppress gene expression. It should be stressed, however, that we are not suggesting a hierarchy of affinity, rather a cooperative association. It has been commonly assumed that the 5mC determinant on DNA is the predominant target of methylation readers ([@bib18]). We propose that the 5mC-dependent reader, MeCP2 co-repressor complex, targets the *pri-miR-208b* promoter to suppress expression in the male heart. Although methylation-mediated transcriptional silencing by MeCP2 is well documented ([@bib47]), recent studies in animal and human cells have shown broader binding preferences that include mRNA ([@bib33]), double-stranded RNA ([@bib21]), short-([@bib23]) and long-ncRNAs ([@bib40]), as well as RNA-dependent spliceosome and miRNA-processing determinants ([@bib72], [@bib8]). Thus, although the conventional view of MeCP2-mediated suppression parallels our observations of DNA methylation in the heart, we hypothesize that RNA methylation could signal MeCP2. So how does *Mhrt* alleviate *pri-miR-208b* suppression in the female heart? As a resolution to this problem, rather than querying MeCP2 interaction solely with methylated DNA, we also assessed the affinity of MeCP2 with *Mhrt* lncRNA as a prime candidate for transcriptional control. This mode of regulation requires specialization, and *Mhrt* is a prime substrate for MeCP2, which is exclusively methylated in females ([Figure 5](#fig5){ref-type="fig"}). This context-dependent default repression ([@bib64]) ensures that *pri-miR-208b* is continually turned off when the promoter is methylated in the (male) heart but turned on when *Mhrt* lncRNA is methylated at CG18 (in the female heart). This is an argument supported by emerging experimental evidence showing RNA methylation as a functional regulatory signal in gene control ([@bib3], [@bib2], [@bib62]) and in keeping with observations we describe for MeCP2-mediated binding of the lncRNA, *Mhrt*. At the molecular level, this mode of regulation could account for the transcriptional robustness in *pri-miR-208b* expression in the female heart as well as the capacity for sex-based expression, notwithstanding identical CGI methylation at the *pri-miR-208b* promoter.Figure 5Working Model Based on Current KnowledgeCooperative DNA and sex-based RNA methylation in the heart. In this study, we identify the *pri-miR-208b* promoter hybrid region and sex-based methylation site (CG18) of *Mhrt* lncRNA. We postulate that the methylation reader MeCP2 and the co-repressor protein complex interact with the *pri-miR-208b* promoter because the *Mhrt* lncRNA is unmethylated at CG18 in the male heart. Methylation at position CG18 of *Mhrt* lncRNA is observed with enriched MeCP2 interaction in the female heart allowing *pri-miR-208b* transcription. *Mhrt* lncRNA is also linked with the SWI/SNF-binding determinant Brg1 ([@bib16]).

RNA methylation of cardiac *Mhrt* extends the functional importance of MeCP2-mediated gene silencing. Nowhere is this more evident than in the signaling molecules that assemble on, and serve to, chromatinize the regulatory cross talk between DNA and RNA ([@bib23], [@bib24]). There are several advantages to MeCP2 coordinating context-dependent regulation. First, 5mC is an effective target for MeCP2. Binding experiments have shown remarkable specificity for the nuclear protein, revealing that a single symmetrical methylated CG site is sufficient for MeCP2 binding ([@bib49], [@bib42]) and that hemi-methylated DNA is a poor substrate ([@bib28]). Second, on methylated CG sites MeCP2 forms a stable complex with HDAC activity to repress transcription. Of note, methylated DNA assembled into chromatin binds MeCP2 and resides in a complex that co-purifies with members of the DNA helicase/ATPase family such as ATRX ([@bib48]), Brahma ([@bib18]), Brg1 ([@bib19]), and Mi-2 ([@bib67]). The ability of MeCP2 to bind to methylated nucleobases to form cell- and tissue-specific regulatory complexes serves to precisely control gene regulation in the heart. In the above examples, CG methylation is the predominant determinant. In other cases, MeCP2 can impart specificity by virtue of interactions with the DNA methylation writing enzyme, DNMT1, to target candidate sequence elements to repress transcription ([@bib56]). Once again, the effectiveness of MeCP2 to achieve gene control relies on its capacity to interpret and tightly bind methylated CG sites. Clearly, methylation-mediated regulation is complicated; however, the diversity in the mechanism of action by the methyl moiety interpreted by MeCP2 represents an attractive solution to connect what appear to be distinct and even seemingly unconnected signaling pathways ([@bib61]). This is strikingly reminiscent of the norepinephrine pathway leading to MeCP2 repression upon activation of α1- and β1-adrenoceptors in cardiomyocytes ([@bib41]). In a mouse model of pathological hypertrophy using TAC the specific CG methylation sites of target genes under direct regulation by MeCP2 remain unaltered. Cardiomyocytes derived from Sham animals show methylation-mediated suppression of *Ppargc1a* by MeCP2, whereas in TAC animals the induction of *miR-212/132* removes MeCP2 from the same methyl-CG sites. Although that study ([@bib41]) did not examine sexual dimorphism in sympathetic cardioprotective pathways, it shows that dynamic signaling gradients can shape MeCP2 regulation and default repression mechanisms in hypertrophic hearts.

Important clinically, pathological signaling can integrate regulatory pathways to connect methylation of assembled chromatin with ncRNAs that silence gene expression by MeCP2. This is highlighted by the chromatinization of the norepinephrine transporter (*NET*) gene by MeCP2 in postural tachycardia syndrome ([@bib23]). Bisulfite sequencing studies in mouse and human cells show *NET* silencing by MeCP2 independent of CGI methylation changes ([@bib17], [@bib5]). Paradoxical to previous knowledge and against the paradigm at the time, these studies showed that altered chromatin states remodeled by helicase proteins together with MeCP2 serve to autonomously silence *NET* expression. To assess the impact of *NET* chromatinization, a protocol was developed to capture RNA-isolated chromatin followed by deep sequencing. *NET*-interacting RNAs identified *let-7i* as a prime target of MeCP2 ([@bib23]). At the molecular level, these studies support the view that DNA helicase or ATPase proteins connect ncRNAs and HDAC activity either to suppress gene transcription ([@bib22]) or to regulate chromatin architecture critical to the nuclear functions associated with gene control.

The regulatory capacity of MeCP2 to co-exist with distinct components on CG methylation sites may be exploited to connect otherwise dipartite regulatory pathways. Here, we report the myocardium-specific lncRNA, *Mhrt*, as a target for MeCP2 recognizing RNA methylation and regulating sex-specific expression of *pri-miR-208b* in the female heart. Binding studies show that the affinity of *Mhrt* RNAmer for MeCP2 is dependent on methylation at CG18, implicating probable role in gene regulation. Therefore, this study is potentially original. We have identified MeCP2 as a physiological target for a cardiac-specific lncRNA. Because methylation of the *Mhrt* lncRNA at CG18 is a substrate for MeCP2, we hypothesize that this affinity for methylated RNA safeguards sex-based cardiac gene suppression.

Recent transcriptome studies have shown widespread RNA methylation in mRNAs and lncRNAs; however, RNA methylation is less abundant than DNA methylation ([@bib62]). Furthermore, RNA methylation at cytosine sites have been shown to influence post-transcriptional gene regulation ([@bib2], [@bib71], [@bib1], [@bib60], [@bib73]). In our study, we observed RNA methylation of *Mhrt* from 25% bisulfite-sequenced clones in the female heart. This resembles the observed frequencies of RNA methylation for the lncRNAs, *HOTAIR* and *XIST* ([@bib57], [@bib3]). Indeed, low-level methylation of *XIST* serves to functionally distinguish methylated from unmethylated versions that bind chromatin-modifying enzymes such as EZH2 and PRC2. In that study ([@bib3]), the reported frequency of *XIST* methylation was approximately 20%. In another study, low-frequency RNA methylation was also observed at specific CG sites in tRNAs ([@bib57]). Based on our experimental observations in the female heart we postulate that the affinity of MeCP2 on methylated *Mhrt* could serve to target specific CG sites for gene regulation.

Although the above example clearly indicates that *XIST* methylation influences the interaction of polycomb-group proteins such as EZH2, their effectiveness to bind chromatinized templates is also subject to histone modifications. Indeed, chromatin content as well as loading of specific co-regulatory complexes serve to integrate regional structures to regulate transcriptional events. For example, in cardiac hypertrophy the activation of α-*MHC* and coordinated suppression of β-*MHC* events are mediated by direct interaction of the *pri-miR-208b* lncRNA to the intergenic bdP ([@bib39]). Specifically, α/β-*MHC* transcriptional responses are regulated by the EZH2/*pri-miR-208b* co-repressive complex to form a suppressive environment at the bdP together with the SWI/SNF chromatin-remodeling determinant Brg1. These distinct changes to the intergenic region mean enhanced H3K27me3 by EZH2 and reduced gene-permissive marks such as H3K4me3 and H3K9/14ac. Thus, we postulate that the importance of sex-based *Mhrt* methylation may serve as an effective regulator of *pri-miR-208b* gene expression for maintaining homeostatic transcriptional expression in the adult heart and serve to integrate these events in pathological remodeling of ventricular hypertrophy.

Limitations of the Study {#sec3.1}
------------------------

Although the properties of MeCP2 affinity with methylated *Mhrt* are considered consistent with the idea of sexual dimorphism regulating *pri-miR-208b* expression, this idea has not yet been tested completely. First, sex-specific methylation of the lncRNA *Mhrt* at CG18 in the female heart remains poorly understood. The challenge now is to understand how the cardiovascular phenotype with respect to hormonal regulation could control gene expression and sex differences ([@bib46]). Second, we also acknowledge that although this study emphasizes RNA methylation-dependent MeCP2 binding in the heart, it now becomes apparent that methylation of other RNA sites could also be prime candidates for default repression by methylation that need to be tested. Although lncRNAs interacting with DNMTs have been documented to regulate DNA methylation ([@bib10]), our results show proof of concept that *Mhrt* methylation is a target for MeCP2 to regulate *pri-miR-208b* expression independent of differential DNA methylation. Furthermore, although we appreciate that CG18 methylation of *Mhrt* was not critically tested using animal models of cardiac disease, future studies should allow us to test the generalizability of site-specific RNA methylation and protein interaction using *in vitro* and *in vivo* experimental models.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Supplemental Information {#appsec2}
========================

Document S1. Transparent Methods and Figures S1--S8

Professor Assam El-Osta is a National Health and Medical Research Council (NHMRC) Senior Research Fellow (1154650), and this work is supported by NHMRC-NSFC International Joint Grant (1113188 and 15070000000090844) and NHMRC grants (1032687 and 526635).

Author Contributions {#sec6}
====================

H.K.N., J.O., and P.M. performed the study design, validation, and data representation; H.K.N. and P.M. performed the ChIP, bisulfite sequencing, and *in vitro* binding assays; J.O. cloned and synthesized Mhrt full-length transcript; J.O., P.M., and A.W.K. prepared the figures; S.A.J., G.S., and X.-J.D. were involved in mouse tissue handling and resources; M.Z. analyzed bisulfite sequencing data; and A.E.-O. was involved in the design, supervision, funding, and writing of the manuscript, which has been reviewed and edited by the co-authors.

Declaration of Interests {#sec7}
========================

The authors declare there is no competing interests.

Supplemental Information can be found online at <https://doi.org/10.1016/j.isci.2019.06.031>.

[^1]: Present address: Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

[^2]: These authors contributed equally

[^3]: Lead Contact
